Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Oncology
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Trending
Biologics
Clinical Development
Ophthalmology
Cell & Gene Therapy
Drug Development
Small Molecule Research & Development
Oncology
Fierce 50
Special Report
Awards Gala
Awards
Outsourcing Awards
Innovation Awards
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Silence Therapeutics
Biotech
Merck KGaA buys Silence in $1.3B deal for blood cancer drug
Germany’s Merck KGaA picked up Silence to the tune of $1.3 billion following the biotech’s mid-stage success for its challenger to Takeda’s Mimrylo.
James Waldron
Oct 19, 2026 8:57am
Silence brings the noise to Takeda with phase 2 blood cancer win
Aug 10, 2026 7:31am
Pfizer RNA leader runs to Replicate—Chutes & Ladders
Dec 19, 2025 8:30am
Silence slows zerlasiran, as Hansoh leaves $1.3B biobucks collab
Feb 27, 2025 8:51am
Silence breaks down phase 1 data on blood disorder prospect
Jun 27, 2024 9:40am
Silence loses Mallinckrodt collab, wins in cardiovascular ph. 2
Mar 13, 2024 8:54am
